Alphabet's AI Drug Discovery Spin-off Isomorphic Labs Secures $600M in Landmark Funding Round
11 Sources
[1]
Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive | TechCrunch
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with participation from GV, and existing investor Google's parent Alphabet, it said. The funding will
[2]
Alphabet's AI Drug Unit Raises $600 Million From OpenAI Backer
Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million, the first time it's taken in external funding. The round was led by Thrive Capital, with participation from Alphabet and its venture arm, GV, Isomorphic Labs said in a
[3]
Google-backed AI drug discovery startup raises $600 million
March 31 (Reuters) - Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday. Google Ventures and Alphabet (GOOGL.O), opens new tab, an existing investor,
[4]
Google DeepMind's drug discovery spin-off Isomorphic Labs raises $600mn
Isomorphic Labs, the drug discovery start-up spun out of Google's DeepMind artificial intelligence unit, has raised $600mn in its first external funding round, as investors bet on the potential for AI to "solve disease". The fundraising for the London-based group, whose chief executive is Nobel
[5]
Alphabet-Backed Isomorphic Labs Raises $600M For AI Drug Development
Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply artificial intelligence to the drug development process. "This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own
[6]
Alphabet spinout Isomorphic Labs raises $600M for its AI drug design engine - SiliconANGLE
Alphabet spinout Isomorphic Labs raises $600M for its AI drug design engine Isomorphic Labs Inc., a healthcare startup that spun out of Alphabet Inc. in 2021, today announced that it has closed a $600 million funding round. OpenAI backer Thrive Capital led the investment. It was joined by
[7]
Google-Backed AI Drug Discovery Startup Raises $600 Million
(Reuters) - Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday. Google Ventures and Alphabet, an existing investor, also participated in the
[8]
Alphabet's Isomorphic Labs raises $600 million to advance AI drug design
The funding will accelerate its AI drug design engine and help advance programs into clinical development. Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug
[9]
Alphabet's Isomorphic Labs raises $600M in first funding round for AI...
Isomorphic Labs, Google's artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the funding round with participation from Google Ventures, the company said in a press release. It will
[10]
Alphabet's Isomorphic Labs secures $600 million in funding By Investing.com
Investing.com -- Isomorphic Labs, a company owned by Alphabet (NASDAQ:GOOGL) Inc. that uses artificial intelligence (AI) to discover drugs, has secured $600 million in a funding round. This marks the first time the company has received external funding. Thrive Capital led the funding round, with
[11]
Alphabet-Backed Isomorphic Labs Raises $600 Million for AI Drug Development
Isomorphic Labs raised $600 million in its first external funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas. The 4-year-old subsidiary of Google parent Alphabet said Monday that U.S. capital venture firm Thrive Capital led the funding round
Share
Copy Link
Isomorphic Labs, the AI-driven drug discovery platform spun out from Google's DeepMind, has raised $600 million in its first external funding round, led by Thrive Capital. The investment aims to accelerate AI-powered drug development and bring AI-designed drugs to clinical trials.
Isomorphic Labs Secures $600M in Landmark Funding Round
Isomorphic Labs, the AI-driven drug discovery platform spun out from Google's DeepMind in 2021, has raised $600 million in its first external funding round. The investment was led by Thrive Capital, with participation from GV and existing investor Alphabet
1
2
. This significant funding injection marks a major milestone for the company and underscores the growing interest in AI-powered drug discovery.Strategic Partnerships and Nobel Recognition
Prior to this funding round, Isomorphic Labs had already made significant strides in the pharmaceutical industry. In 2024, the company secured strategic partnerships with pharmaceutical giants Eli Lilly and Novartis, potentially generating up to $3 billion in milestone payments for access to its AI model
1
. The company's founder, Demis Hassabis, along with DeepMind researcher John Jumper, received a Nobel Prize in chemistry in 2024 for their work on AlphaFold, an AI model that predicts the three-dimensional structures of proteins1
4
.Accelerating AI-Powered Drug Discovery
The substantial funding will be used to accelerate the development of Isomorphic's AI drug design engine and support the company's ambitious goal of bringing AI-discovered drugs to clinical trials
1
. Demis Hassabis, who serves as both the founder and CEO of Isomorphic Labs, has suggested that the company aims to have AI-designed drugs in clinical trials by the end of 20253
4
.Expanding Research and Talent Acquisition
While Isomorphic Labs didn't necessarily need the capital, according to Hassabis, the extra funding will help the company hire top research scientists and expand its team
1
4
. The investment will also be used to accelerate AI research and development in drug design, furthering the company's mission of "solving all disease with the help of AI"4
5
.Related Stories
Industry Impact and Future Prospects
The funding round for Isomorphic Labs is among the largest for a UK AI company and reflects the broader trend of significant investments in AI-driven drug discovery startups. Other notable raises in the past year include Xaira Therapeutics securing a $1 billion Series A and Formation Bio locking up $372 million in a Series D
5
.Financial Details and Ownership Structure
While the exact valuation of Isomorphic Labs was not disclosed, Alphabet remains the majority shareholder following this funding round
4
. In its first full year of operations in 2023, the company reported losses of £60 million, up from £17 million a year earlier, with R&D costs growing to £49 million and staff costs tripling to £20 million4
.As the race to leverage AI in drug discovery intensifies, Isomorphic Labs' substantial funding and strategic partnerships position it as a key player in this rapidly evolving field. The company's progress will be closely watched as it works towards its goal of revolutionizing drug development through artificial intelligence.
References
Summarized by
Navi
[1]
Related Stories
Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery and Advance Clinical Trials
09 May 2026•Startups
Google DeepMind's Isomorphic Labs Nears Human Trials for AI-Designed Drugs
07 Jul 2025•Science and Research
Google DeepMind CEO Predicts AI-Designed Drugs in Clinical Trials by 2025
22 Jan 2025•Science and Research
Recent Highlights
1
OpenAI Claims AI Math Breakthrough on Navier-Stokes, Sparks Controversy Over Credit and Future of Research
Science and Research
2
Anthropic Researcher Quits, Warns Self-Improving AI Poses Existential Risk to Humanity
Policy and Regulation
3
Nvidia CEO Jensen Huang Declares AGI Has Arrived With OpenAI's GPT-6 Astra Release
Technology
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
